Clinical trials / NCT03755726
Recruiting

A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort

This registry aims to provide the first prospective, multicentric database of patients with malignant hypertension. It will allow to assess modern epidemiology of the disease, diversity of current management and care pathway, to deepen our pathophysiological knowledges, to modernize the definition of this form of hypertension and its diagnostic criteria. The network that will emerge will finally lead to the opportunity of setting up therapeutic trials and establishing recommendations based on solid scientific…

ClinicalTrials.gov IDNCT03755726
PhaseNot Applicable
Enrollment1200
SponsorCentre Hospitalier de PAU
Age18 Years and older
SexALL
I'm interested View official listing

Conditions studied

Malignant Hypertension

About this study

This registry aims to provide the first prospective, multicentric database of patients with malignant hypertension. It will allow to assess modern epidemiology of the disease, diversity of current management and care pathway, to deepen our pathophysiological knowledges, to modernize the definition of this form of hypertension and its diagnostic criteria. The network that will emerge will finally lead to the opportunity of setting up therapeutic trials and establishing recommendations based on solid scientific evidence.

Primary outcomes

Eligibility information

Inclusion Criteria: * Malignant hypertension according to the classic definition (Severe hypertension, above 180/110 associated with severe hypertensive retinopathy) * Severe hypertension (above 180/110) associated with acute damage of 3 target organ due to high blood pressure Exclusion Criteria: * Age \< 18 years old * Patients who cannot freely give their consent, or patients who refuse to participate * Dialysis

Study locations

Showing 10 of 37 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-28.